From the IASLC Tobacco Control Committee

        The study evaluated 721 young people in New South Wales recruited online regarding their access to vaping products, product type used, and factors associated with vaping and smoking. Ever-vaper was reported in 32% of the study population, with 54% of them had never smoked before starting vaping. Ever-smokers were seven times more likely to be ever-vapers versus those who had never smoked; ever-vapers were 18 times more likely to be ever-smokers versus those who had never vaped. Age and being Aboriginal or Torres Strait Islander were independently associated with ever-vaping, whereas being male was associated with ever-smoking. Disposable products were used by 86% of the ever-vapers. More than half of the ever-vapers got the last vape they used from their friends and had used a vape that they knew contained nicotine. “Flavorings and taste” was the most important vape feature. To conclude, vaping was the strongest risk factor for smoking and vice versa. Stronger enforcement of policies is necessary to protect young people from vaping products.
        To read this article in full you will need to make a payment

        Purchase one-time access:

        Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
        One-time access price info
        • For academic or personal research use, select 'Academic and Personal'
        • For corporate R&D use, select 'Corporate R&D Professionals'


        Subscribe to Journal of Thoracic Oncology
        Already a print subscriber? Claim online access
        Already an online subscriber? Sign in
        Institutional Access: Sign in to ScienceDirect


          • Rigotti N.A.
          • Chang Y.
          • Davis E.M.
          • et al.
          Comparative effectiveness of postdischarge smoking cessation interventions for hospital patients: the helping HAND 4 randomized clinical trial.
          JAMA Intern Med. 2022; 182: 814-824
        1. Lopes LC, Zhang Y, Ross S, et al. Varenicline for tobacco-dependent adults who are not ready to discontinue use: a systematic review and meta-analysis [e-pub ahead of print]. Ann Am Thorac Soc., accessed October 13, 2022.

          • Ebbert J.O.
          • Hughes J.R.
          • West R.J.
          Varenicline for smoking reduction prior to cessation--reply.
          JAMA. 2015; 313: 2285-2286
          • PDQ Screening and Prevention Editorial Board
          • National Cancer Institute
          Cigarette smoking: health risks and how to quit (PDQ®): health professional version.
          (Accessed October 13, 2022)
        2. From the IASLC tobacco control committee.
          J Thorac Oncol. 2021; 16: 1598-1600
          • Stone E.
          • Paul C.
          The tobacco endgame—a new paradigm for smoking cessation in cancer clinics.
          Curr Oncol. 2022; 29: 6325-6333
          • WHO. MPOWER
          (Accessed October 13, 2022)
          • New Zealand Parliament
          Smokefree environments and regulated products (smoked tobacco) amendment bill.
          (Accessed October 13, 2022)
          • GOV.UK
          The Khan review: making smoking obsolete.
          (Accessed October 13, 2022)
          • GOV.UK
          Making smoking obsolete: summary.
          (Accessed October 13, 2022)
          • Edwards R.
          • Hopkinson N.
          The Khan review: the UK government must act now for a smokefree future.
          Lancet. 2022; 400: 979-981
          • U.S. Food and Drug Administration
          FDA announces plans for proposed rule to reduce addictiveness of cigarettes and other combusted tobacco products.
          (Accessed October 13, 2022)
        3. Brailovskaia J, Swarlik VJ, Grethe GA, Schillack H, Margraf J. Experimental longitudinal evidence for causal role of social media use and physical activity in COVID-19 burden and mental health [e-pub ahead of print]. Z Gesundh Wiss., accessed October 13, 2022.